Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clopidogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 2/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.96 |
| ▸ | DRD1 | P21728 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | HTR2B | P41595 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.96 |
| ▸ | THRB | P10828 | 1/20 | 0.96 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.96 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopidogrel SCHEMBL3377942 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL28005760 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1130036 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL27927313 | 0.98 | ABCB11 (0.96) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL2087706 | 0.98 | ABCB11 (0.96) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL754557 | 0.98 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL29793709 | 0.98 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031319 | 0.98 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL4769 | 0.98 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031641 | 0.98 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897613-B2 | Crystalline polymorphs of clopidogrel | GENERICS [UK] LIMITED (GB) | 2011-03-01 | — | — | US | claimed |
| EP-1618113-B1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | GENERICS UK LTD (GB) | 2010-11-10 | — | — | EP | claimed |
| EP-1704152-A2 | CRYSTALLINE CLOPIDOGREL HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2006-09-27 | — | — | EP | claimed |
| US-20060154957-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-07-13 | — | — | US | claimed |
| WO-2006034451-A2 | CRYSTALLINE CLOPIDOGREL HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-30 | — | — | WO | claimed |
| EP-2291177-A2 | STABLE PHARMACEUTICAL COMPOSITIONS AND THEIR PROCESSES FOR PREPARATION SUITABLE FOR INDUSTRIAL SCALE | Farmaprojects, S.A. (ES) | 2011-03-09 | — | — | EP | disclosed |
| EP-1618113-B1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | GENERICS UK LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009135646-A2 | STABLE PHARMACEUTICAL COMPOSITIONS AND THEIR PROCESSES FOR PREPARATION SUITABLE FOR INDUSTRIAL SCALE | FARMAPROJECTS, SA (ES) | 2009-11-12 | — | — | WO | disclosed |
| US-20090187022-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS. | 2009-07-23 | — | — | US | disclosed |
| US-20080306268-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-12-11 | — | — | US | disclosed |
| US-20080300409-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-12-04 | — | — | US | disclosed |
| US-20070088049-A1 | POLYMORPHIC FORMS OF METHYL (+)-(S) - ALPHA - (2-CHLOROPHENYL)-6, 7-DIHYDROTHIENO [3,2-C]PYRIDINE-5(4H) ACETATE HYDROBROMIDE, CLOPIDOGREL HYDROBROMIDE | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | US | disclosed |
| EP-1756116-A1 | POLYMORPHIC FORMS OF METHYL(+)-(S)-ALPHA-(2-CHLOROPHENYL)-6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-5(4H) ACETATE HYDROBROMIDE, CLOPIDROGEL HYDROBROMIDE | Sanofi-Aventis (FR) | 2007-02-28 | — | — | EP | disclosed |
| EP-1704152-A2 | CRYSTALLINE CLOPIDOGREL HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2006-09-27 | — | — | EP | disclosed |
| US-20060154957-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-07-13 | — | — | US | disclosed |
| WO-2006034451-A2 | CRYSTALLINE CLOPIDOGREL HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005103058-A1 | POLYMORPHIC FORMS OF METHYL (+) - (S) -ALPHA- (2-CHLOROPHENYL) -6, 7-DIHYDROTHIENO `3,2-C!PYRIDINE-584H) ACETATE HYDROBROMIDE, CLOPIDROGEL HYDROBROMIDE | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154957-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | P2RY12 9/4885ABCB11 990/4885OPRM1 3752/4885 |
| US-20070088049-A1 | POLYMORPHIC FORMS OF METHYL (+)-(S) - ALPHA - (2-CHLOROPHENYL)-6, 7-DIHYDROTHIENO [3,2-C]PYRIDINE-5(4H) ACETATE HYDROBROMIDE, CLOPIDOGREL HYDROBROMIDE | P2RY11, P2RY4, P2RY13 | P2RY12 4/4885ABCB11 348/4885OPRM1 1624/4885 |
| US-20090187022-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | P2RY12 9/4885ABCB11 990/4885OPRM1 3752/4885 |
| US-20080306268-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | P2RY12 9/4885ABCB11 990/4885OPRM1 3752/4885 |
| US-20080300409-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | P2RY12 9/4885ABCB11 990/4885OPRM1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.